Accelerated cancer registration from the National Disease Registration Service to support the NHS-Galleri trial

Abstract Purpose High-quality population-based cancer registration data is crucial for cancer research. We describe the methodology that the National Disease Registration Service (NDRS) established to accelerate provision of cancer registration data in England to support timely analysis of the NHS-Galleri trial ( NCT05611632 ), assessing the clinical utility of a multi-cancer early detection test for population screening. Methods NDRS established two accelerated cancer registration products for trial participants: ‘Expedited Core’ (providing complete stage data 6 months after diagnosis) and ‘Expedited Comprehensive’ (providing ≥6 months of follow-up clinical pathway data 11 months after diagnosis). NDRS used pre-existing data sources and methodology, plus enhanced dedicated data liaison support. Timeliness and concordance of accelerated data was assessed 6, 11, and ≥19 months after diagnosis. Results At 6–10 months after diagnosis, most (98.0%) registrations achieved Expedited Core status; at >10 months, all (100%) registrations were Expedited Comprehensive. For fact of malignant cancer and stage III/IV diagnoses, concordance between registrations at 6 and ≥19 months was 96.7% and 95.6%, respectively. Conclusions NDRS delivered staged cancer registration data 6 months after diagnosis. High concordance at 6, 11, and 19 months provides confidence in the accelerated data. This supports reporting NHS-Galleri findings more promptly than possible via routine data. Highlights NDRS accelerated cancer registration data provision to support a major clinical trial Routine cancer registration data is typically available 18–20 months after diagnosis Accelerated staged cancer registration data was available 6 months after diagnosis Six, 11 & 19-month data concordance was high, indicating good data quality This data successfully supported trial analyses but required additional resource